Girihlet Inc. was founded in 2012 with a core mission to advance the understanding and treatment of complex immune diseases through innovative diagnostic tools and deep sequencing technology. The company offers products like ImmuneScanner, a diagnostic tool designed to monitor autoimmune treatments, helping patients and doctors select the most effective therapies. Girihlet focuses on manufacturing in vitro and in vivo diagnostic substances, targeting the healthcare and biomedical research markets.
Notable affiliations include a collaboration with the Mayo Clinic to study the effects of treatments on Ankylosing Spondylitis using ImmuneScanner. Girihlet's key achievements include developing a multi-dimensional platform that accelerates the discovery of disease-monitoring and therapeutic strategies for immune diseases. Their impact lies in enhancing personalized medicine approaches and improving outcomes for patients with autoimmune conditions.
